◀ Back to BCL10
BCL10 — FASLG
Text-mined interactions from Literome
Biswas et al., Mol Cell Biochem 2001
(Breast Neoplasms...) :
Overexpression of
Bcl-XL leads to inhibition of paclitaxel induced
FasL expression and apoptosis
Chandrasekar et al., J Biol Chem 2004
(Inflammation) :
Treatment of HCMEC with IL-18 increases 1 ) NF-kappaB DNA binding activity ; 2 ) induces kappaB-driven luciferase activity ; 3 ) induces IL-1beta and TNF-alpha expression via NF-kappaB activation ; 4 ) inhibits antiapoptotic Bcl-2 and Bcl-X ( L ) ; 5 ) up-regulates proapoptotic Fas, Fas-L, and
Bcl-X ( S ) expression ; 6 )
induces fas and
Fas-L promoter activities via NF-kappaB activation ; 7 ) activates caspases-8, -3, -9, and BID ; 8 ) induces cytochrome c release into the cytoplasm ; 9 ) inhibits FLIP ; and 10 ) induces HCME cell death by apoptosis as seen by increased annexin V staining and increased levels of mono- and oligonucleosomal fragmented DNA
Gravina et al., Prostate 2010
(Neoplasms, Experimental...) :
This combined treatment up-regulated the expression of
FasL , phospho-FADD, p16 ( INKA ), Bax, Bak, and p21 ( WAF1 ), and
inhibited FLIP, Bcl-2, and
Bcl-XL expression
Fulda et al., Cancer Res 1998
(Neuroblastoma) :
After Doxo treatment, enhanced
CD95/CD95-L expression and caspase-8 activation were not
blocked by Bcl-2 or
Bcl-X ( L ) and were found in cells with a mitochondrial transmembrane potential ( delta psi ( m ) ) that was still normal ( delta psi ( m ) high cells )